BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma WW, Hidalgo M. Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol 2007; 13(44): 5845-5856 [PMID: 17990350 DOI: 10.3748/wjg.v13.i44.5845] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Rupertus K, Dahlem C, Menger MD, Schilling MK, Kollmar O. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation. Ann Surg Oncol. 2009;16:2629-2637. [PMID: 19551445 DOI: 10.1245/s10434-009-0564-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
2 Whipple C, Korc M. Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg. 2008;393:901-910. [PMID: 18210149 DOI: 10.1007/s00423-008-0280-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
3 Nasr AO, Dillon MF, Conlon S, Downey P, Chen G, Ireland A, Leen E, Bouchier-hayes D, Walsh TN. Acid suppression increases rates of Barrett’s esophagus and esophageal injury in the presence of duodenal reflux. Surgery 2012;151:382-90. [DOI: 10.1016/j.surg.2011.08.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
4 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 146] [Article Influence: 21.8] [Reference Citation Analysis]
5 Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD. eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila) 2014;7:169-78. [PMID: 24282255 DOI: 10.1158/1940-6207.CAPR-13-0299] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
6 van Geer MA, Bakker CT, Koizumi N, Mizuguchi H, Wesseling JG, Oude Elferink RP, Bosma PJ. Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivoWorld J Gastroenterol 2009; 15(22): 2754-2762 [PMID: 19522026 DOI: 10.3748/wjg.15.2754] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
7 Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol 2010;3:373-9. [PMID: 21151476 DOI: 10.1593/tlo.10196] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
8 Martins SF, Reis RM, Rodrigues AM, Baltazar F, Filho AL. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol 2011; 2(6): 272-280 [PMID: 21773077 DOI: 10.5306/wjco.v2.i6.272] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
9 Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res 2009;69:5073-81. [PMID: 19491272 DOI: 10.1158/0008-5472.CAN-08-3839] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
10 Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009;9:247-261. [PMID: 19192962 DOI: 10.1586/14737140.9.2.247] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
11 Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P. Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases. Prog Med Chem 2009;48:81-131. [PMID: 21544958 DOI: 10.1016/s0079-6468(09)04803-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
12 Dudek H, Wong DH, Arvan R, Shah A, Wortham K, Ying B, Diwanji R, Zhou W, Holmes B, Yang H, Cyr WA, Zhou Y, Shah A, Farkiwala R, Lee M, Li Y, Rettig GR, Collingwood MA, Basu SK, Behlke MA, Brown BD. Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo. Mol Ther 2014;22:92-101. [PMID: 24089139 DOI: 10.1038/mt.2013.233] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
13 Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011;37:63-74. [PMID: 20570444 DOI: 10.1016/j.ctrv.2010.05.001] [Cited by in Crossref: 315] [Cited by in F6Publishing: 305] [Article Influence: 26.3] [Reference Citation Analysis]
14 Francois E, Bennouna J, Chamorey E, Etienne-Grimaldi MC, Renée N, Senellart H, Michel C, Follana P, Mari V, Douillard JY, Milano G. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. Chemotherapy 2012;58:371-80. [PMID: 23235319 DOI: 10.1159/000343969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]